Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
114.50
+0.17 (0.15%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Arcellx Employees
Arcellx had 209 employees as of December 31, 2025. The number of employees increased by 46 or 28.22% compared to the previous year.
Employees
209
Change (1Y)
46
Growth (1Y)
28.22%
Revenue / Employee
$106,632
Profits / Employee
-$1,095,378
Market Cap
6.70B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 209 | 46 | 28.22% |
| Dec 31, 2024 | 163 | 33 | 25.38% |
| Dec 31, 2023 | 130 | 32 | 32.65% |
| Dec 31, 2022 | 98 | 20 | 25.64% |
| Dec 31, 2021 | 78 | 47 | 151.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Rhythm Pharmaceuticals | 414 |
| CRISPR Therapeutics AG | 393 |
| Immunovant | 362 |
| Krystal Biotech | 295 |
| Cogent Biosciences | 258 |
| Kymera Therapeutics | 238 |
ACLX News
- 5 days ago - Top 2 Health Care Stocks That May Crash This Quarter - Benzinga
- 6 days ago - Baron Health Care Fund Q4 2025 Recent Activity - Seeking Alpha
- 6 days ago - Baron Health Care Fund Q4 2025 Contributors And Detractors - Seeking Alpha
- 14 days ago - Here's Why Shares of Arcellx Are Up Almost 80% Today - Investopedia
- 14 days ago - Why is Arcellx stock up 80% today? Gilead's $7.8B answer - Invezz
- 14 days ago - Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - Reuters
- 14 days ago - Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion - WSJ
- 14 days ago - Gilead to acquire Arcellx for $7.8 billion - Reuters